The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:1009-1010 October 12, 1995 Number 15
NextNext

Is the Use of t-PA as Compared with Streptokinase Cost Effective?

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Lee, T. H.
-Related Article
by Mark, D. B.
To the Editor: The conclusion by Mark et al. in their analysis of the cost effectiveness of thrombolytic therapy for acute myocardial infarction (May 25 issue)1 that the routine use of accelerated tissue plasminogen activator (t-PA) in patients with acute myocardial infarction would provide 3.5 million additional years of life after myocardial infarction appears to be a gross overstatement of the annual survival benefit. The authors' data do not support the contention that each of the 250,000 potentially eligible recipients of this therapy would gain 14 additional years of life from this treatment.

Instead, the data from the Global Utilization . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.